[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 500", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 825 6990", "website": "https://www.tenayatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Mr. Faraz  Ali M.B.A.", "age": 50, "title": "CEO & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 890059, "exercisedValue": 0, "unexercisedValue": 1142905}, {"maxAge": 1, "name": "Michelle  Corral", "title": "Vice President of Investor Relationship & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Drimmer J.D.", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joanna  Auch", "title": "Senior Vice President of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jay  Vora MBA, Ph.D.", "age": 57, "title": "Senior Vice President of Portfolio & Program Management", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew J. Pollman M.D., M.S.", "age": 60, "title": "Senior Vice President of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sunita  Sethi Pharm.D.", "title": "Senior Vice President of Regulatory", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Naymisha  Patel M.B.A.", "title": "Senior Vice President of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.38, "open": 4.25, "dayLow": 3.97, "dayHigh": 4.3, "regularMarketPreviousClose": 4.38, "regularMarketOpen": 4.25, "regularMarketDayLow": 3.97, "regularMarketDayHigh": 4.3, "beta": 2.61, "forwardPE": -2.3314917, "volume": 382522, "regularMarketVolume": 382522, "averageVolume": 536593, "averageVolume10days": 289570, "averageDailyVolume10Day": 289570, "bid": 4.2, "ask": 4.25, "bidSize": 400, "askSize": 200, "marketCap": 331343840, "fiftyTwoWeekLow": 1.66, "fiftyTwoWeekHigh": 8.091, "fiftyDayAverage": 5.1445, "twoHundredDayAverage": 3.7229, "currency": "USD", "enterpriseValue": 239120112, "floatShares": 42735551, "sharesOutstanding": 78517504, "sharesShort": 3365904, "sharesShortPriorMonth": 2551906, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0429, "heldPercentInsiders": 0.01533, "heldPercentInstitutions": 0.77204, "shortRatio": 7.83, "shortPercentOfFloat": 0.0616, "impliedSharesOutstanding": 78517504, "bookValue": 2.04, "priceToBook": 2.0686274, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -124084000, "trailingEps": -1.68, "forwardEps": -1.81, "enterpriseToEbitda": -1.952, "52WeekChange": -0.20602071, "SandP52WeekChange": 0.21080327, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TNYA", "underlyingSymbol": "TNYA", "shortName": "Tenaya Therapeutics, Inc.", "longName": "Tenaya Therapeutics, Inc.", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2244c099-c937-391d-9d2b-ae91c15b1439", "messageBoardId": "finmb_409125654", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.22, "targetHighPrice": 40.0, "targetLowPrice": 7.0, "targetMeanPrice": 19.43, "targetMedianPrice": 18.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 104642000, "totalCashPerShare": 1.333, "ebitda": -122506000, "totalDebt": 12424000, "quickRatio": 4.603, "currentRatio": 4.908, "debtToEquity": 8.911, "returnOnAssets": -0.36486, "returnOnEquity": -0.6483, "freeCashflow": -60779624, "operatingCashflow": -102072000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]